Sphenopalatine ganglion (SPG) blocks: Evidence and implementation for acute migraine treatment in the primary care setting.

Abstract

Background: Sphenopalatine ganglion (SPG) blocks may be effective and affordable treatments for acute migraine but are rarely used in the primary care setting, making them inaccessible treatment for those suffering from migraine.

Objective: To outline evidence for the use of SPG block in the treatment of acute migraine. To determine the feasibility and effectiveness of primary care in-office and at-home SPG block administration.

Methods: A retrospective chart review of patients receiving in-office or at-home SPG block to treat acute migraine was completed. Pre- and post-treatment pain measurements were the primary outcome, along with patient-reported adverse effects.

Results: Results from this study revealed that 87% of SPG block administrations (via catheter and atomizer) resulted in pain relief with minimal adverse effects. Methods and materials for catheter and atomizer administration of SPG blocks are outlined, in addition to tips for integrating this service into primary care practices.

Conclusions: This study showed that SPG blocks may be administered effectively in primary care settings or at home with proper patient education and are an effective treatment modality to decrease pain associated with acute migraine.